Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5062
Abstract: Poly ADP‐ribose polymerase inhibitors (PARPis) have significantly improved clinical effects in gynecological oncology. However, PARPis could also induce severe organ system toxicities, including the hematological system. Our study aimed to extensively characterize the hematological toxicities… read more here.
Keywords: hematological toxicities; system; toxicities parp; real world ... See more keywords
Hematological toxicities associated with linezolid therapy in adults: key findings and clinical considerations
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2023.2181160
Abstract: ABSTRACT Introduction Linezolid can cause serious adverse effects including thrombocytopenia and anemia. Here, we focus specifically on linezolid-related hematological toxicity in adult patients requiring prolonged drug treatment. Areas covered We review the available evidence on… read more here.
Keywords: hematological toxicities; linezolid therapy; associated linezolid; thrombocytopenia ... See more keywords
The risks of hematological toxicities of nivolumab in cancer patients: A PRISMA-compliant meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000032393
Abstract: Background: Nivolumab is the human programmed cell death-1 (PD-1)-blocking antibody showing significant effect in many refractory cancers. However, little is known about its risks of hematological toxicities, rare but clinically serious and potentially life-threatening adverse… read more here.
Keywords: hematological toxicities; meta analysis; neutropenia leukopenia; anemia neutropenia ... See more keywords
Abstract P6-10-03: Germline(g)BRCA1/2mutations (m) and hematological toxicities in patients (pts) with triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT)
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs19-p6-10-03
Abstract: Background: BRCA1/2 genes play a central role in DNA repair. Therefore, pts harboring gBRCA1/2m treated with chemotherapy might be at higher risk of acute hematological toxicities due to the lower level of functional BRCA1/2 protein… read more here.
Keywords: chemotherapy; breast cancer; rate; brca1 ... See more keywords
Risk of hematological toxicities and febrile neutropenia in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.31_suppl.207
Abstract: 207Background: Majority of breast cancers express the estrogen receptor or progesterone receptor. CDK4/6 signaling plays a role in endocrine therapy resistance and the benefit of inhibition of these pathways has been proven in studies. Yet… read more here.
Keywords: hematological toxicities; analysis; systematic review; toxicities febrile ... See more keywords
Effect of renin-angiotensin system inhibitors on pemetrexed plus platinum-induced hematological toxicities: a multicenter retrospective study using three propensity score analyses.
Sign Up to like & getrecommendations! Published in 2021 at "Die Pharmazie"
DOI: 10.1691/ph.2021.1409
Abstract: Hematological toxicities induced by pemetrexed plus platinum therapy remain a critical issue in clinical practice. We hypothesized that inhibition of the renin-angiotensin system (RAS) can ameliorate pemetrexed-induced hematological toxicities through drug-drug interactions involving organic anion… read more here.
Keywords: hematological toxicities; renin angiotensin; plus platinum; pemetrexed plus ... See more keywords
Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.762366
Abstract: Background Cisplatin-based concurrent chemoradiotherapy is standard of care for locally advanced head and neck cancers (LAHNC). Nedaplatin, lobaplatin and nimotuzumab have shown anti-cancer effect with less gastrointestinal toxicity and nephrotoxicity. However, the profile of hematological… read more here.
Keywords: nedaplatin lobaplatin; hematological toxicities; group; cisplatin nedaplatin ... See more keywords